Šalis: Malta
kalba: anglų
Šaltinis: Medicines Authority
OCTREOTIDE
Novartis Ireland Limited Vista Building, Elm Park, Merrion Road, Ballsbridge, Dublin 4,, Ireland
H01CB02
OCTREOTIDE 0.5 mg/ml
SOLUTION FOR INFUSION OR INJECTION
OCTREOTIDE 0.5 mg/ml
POM
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
Authorised
2005-10-27
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT SANDOSTATIN® 500 MICROGRAM/1 ML, SOLUTION FOR INJECTION/INFUSION octreotide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Sandostatin is and what it is used for 2. What you need to know before you use Sandostatin 3. How to use Sandostatin 4. Possible side effects 5. How to store Sandostatin 6. Contents of the pack and other information 1. WHAT SANDOSTATIN IS AND WHAT IT IS USED FOR Sandostatin is a synthetic compound derived from somatostatin, a substance normally found in the human body which inhibits the effects of certain hormones such as growth hormone. The advantages of Sandostatin over somatostatin are that it is stronger and its effects last longer. SANDOSTATIN IS USED • in ACROMEGALY , a condition where the body produces too much growth hormone. Normally, growth hormone controls growth of tissues, organs, and bones. Too much growth hormone leads to an increase in the size of bones and tissues, especially in the hands and feet. Sandostatin markedly reduces the symptoms of acromegaly, which include headache, excessive perspiration, numbness of the hands and feet, tiredness, and joint pain. • to relieve symptoms associated with some TUMOURS OF THE GASTROINTESTINAL TRACT (e.g. carcinoid tumours, VIPomas, glucagonomas, gastrinomas, insulinomas). In these conditions, there is overproduction of some specific hormones and other related substances by the stomach, bowels, or pancreas. This overproduction upsets the natural hormonal Perskaitykite visą dokumentą
Page 1 of 14 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT SANDOSTATIN 50 microgram/1 ml, solution for injection/infusion SANDOSTATIN 100 microgram/1 ml, solution for injection/infusion SANDOSTATIN 500 microgram/1 ml, solution for injection/infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ampoule of 1 ml contains 50 micrograms octreotide (as octreotide acetate) One ampoule of 1 ml contains 100 micrograms octreotide (as octreotide acetate) One ampoule of 1 ml contains 500 micrograms octreotide (as octreotide acetate) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection/infusion. Clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic control and reduction of growth hormone (GH) and IGF-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Sandostatin is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastro-entero-pancreatic (GEP) endocrine tumours, e.g. carcinoid tumours with features of the carcinoid syndrome (see section 5.1). Sandostatin is not an anti-tumour therapy and is not curative in these patients. Prevention of complications following pancreatic surgery. Emergency management to stop bleeding and to protect from re-bleeding owing to gastro-oesophageal varices in patients with cirrhosis. Sandostatin is to be used in association with specific treatment such as endoscopic sclerotherapy. Treatment of TSH-secreting pituitary adenomas: • when secretion has not normalised after surgery and/or radiotherapy; • in patients in whom surgery is inappropriate; • in irradiated patients, until radiotherapy is effective. Page 2 of 14 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Acromegaly _ Initially 0.05 to 0.1 mg by subcutaneous (s.c.) injection every 8 or 12 hours. Dosage adjustment should be based on mon Perskaitykite visą dokumentą